Deciphering the data in EGFR - Mutant NSCLC

Watch experts in lung cancer discuss the latest developments in the management of patients with EGFR-mutant non-small-cell lung cancer (NSCLC), including the role of biomarker testing and the evolving treatment paradigms in both locally-advanced and metastatic disease.

An independent medical education grant from AstraZeneca.
This activity is jointly provided by USF Health and touchIME.